AXGN
VENTE TOTALE: 31 003 titres (~1 461 498,52 $ US)
- Insiders
- TYNDALL JOSEPH A., Wendell Amy McBride, Weiler Kathy Johnson
- Total bought
- —
- Total sold
- $1,461,499
- Last activity
- 2026-09-02
- Last synced
-
2026-09-08 09:54:45
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-08
AXGN combines a weak catalyst score (25, NONE type) with deeply concerning fundamentals — persistent net losses, negative interest coverage, and an EV/EBITDA above 8000 — making the 75 liquidity score insufficient to…
The first sentence of the analysis written for AXGN on 2026-09-08 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 74.3% | 75.8% | 76.6% | 78.5% | 82.0% | |
| Ebit Margin | -3.6% | -0.9% | -11.9% | -20.4% | -20.1% | |
| Ebitda Margin | 0.1% | 3.2% | -8.4% | -16.9% | -16.4% | |
| Operating Profit Margin | -3.5% | -1.8% | -13.5% | -21.4% | -20.0% | |
| Pretax Profit Margin | -7.0% | -5.3% | -13.7% | -20.9% | -21.2% | |
| Continuous Operations Profit Margin | -7.0% | -5.3% | -13.7% | -20.9% | -21.2% | |
| Net Profit Margin | -7.0% | -5.3% | -13.7% | -20.9% | -21.2% | |
| Bottom Line Profit Margin | -7.0% | -5.3% | -13.7% | -20.9% | -21.2% | |
| Current Ratio | 5.112 | 3.241 | 2.892 | 4.129 | 5.230 | |
| Quick Ratio | 3.313 | 2.157 | 2.136 | 3.333 | 4.543 | |
| Solvency Ratio | -0.081 | -0.021 | -0.160 | -0.255 | -0.233 | |
| Cash Ratio | 1.509 | 0.900 | 1.020 | 0.643 | 1.348 | |
| Price To Earnings Ratio | -96.265 | -71.652 | -13.392 | -14.464 | -14.415 | |
| Price To Earnings Growth Ratio | -2.013 | 1.305 | 0.513 | -2.350 | -1.730 | |
| Forward Price To Earnings Growth Ratio | -2.013 | 1.305 | 0.513 | -2.350 | -1.730 | |
| Price To Earnings Diluted Ratio | -96.265 | -71.652 | -13.392 | -14.464 | -14.415 | |
| Price To Earnings Diluted Growth Ratio | -2.013 | 1.305 | 0.513 | -2.350 | -1.730 | |
| Price To Book Ratio | 11.698 | 7.019 | 3.061 | 4.158 | 3.431 | |
| Price To Sales Ratio | 6.693 | 3.893 | 1.842 | 3.031 | 3.032 | |
| Price To Free Cash Flow Ratio | -513.885 | 66,306.531 | -14.193 | -11.254 | -9.238 | |
| Price To Operating Cash Flow Ratio | 1,856.189 | 160.832 | -51.235 | -26.142 | -28.809 | |
| Debt To Assets Ratio | 0.305 | 0.337 | 0.352 | 0.345 | 0.324 | |
| Debt To Equity Ratio | 0.525 | 0.661 | 0.724 | 0.668 | 0.599 | |
| Debt To Capital Ratio | 0.344 | 0.398 | 0.420 | 0.400 | 0.375 | |
| Long Term Debt To Capital Ratio | 0.273 | 0.314 | 0.328 | 0.312 | 0.285 | |
| Financial Leverage Ratio | 1.721 | 1.961 | 2.057 | 1.935 | 1.848 | |
| Working Capital Turnover Ratio | 2.722 | 2.969 | 2.411 | 1.565 | 1.131 | |
| Operating Cash Flow Ratio | 0.034 | 0.148 | -0.188 | -0.676 | -0.552 | |
| Operating Cash Flow Sales Ratio | 0.004 | 0.024 | -0.036 | -0.116 | -0.105 | |
| Free Cash Flow Operating Cash Flow Ratio | -3.612 | 0.002 | 3.610 | 2.323 | 3.119 | |
| Debt Service Coverage Ratio | 0.025 | 0.741 | -4.701 | -37.614 | -15.404 | |
| Interest Coverage Ratio | -1.019 | -0.401 | -7.570 | -47.607 | -18.743 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.012 | 0.066 | -0.082 | -0.238 | -0.199 | |
| Capital Expenditure Coverage Ratio | 0.217 | 1.002 | -0.383 | -0.756 | -0.472 | |
| Dividend Paid And Capex Coverage Ratio | 0.217 | 1.002 | -0.383 | -0.756 | -0.472 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 8,017.220 | 126.748 | -24.845 | -20.116 | -20.149 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 74.3% | ▼-1.5% | ▼-3.1% |
| Ebit Margin | -3.5% | ▼-2.6% | ▲7.8% |
| Ebitda Margin | 0.1% | ▼-3.2% | ▲7.8% |
| Operating Profit Margin | -3.5% | ▼-1.7% | ▲8.5% |
| Pretax Profit Margin | -7.0% | ▼-1.7% | ▲6.6% |
| Continuous Operations Profit Margin | -7.0% | ▼-1.7% | ▲6.6% |
| Net Profit Margin | -7.0% | ▼-1.7% | ▲6.6% |
| Bottom Line Profit Margin | -7.0% | ▼-1.7% | ▲6.6% |
| Current Ratio | 5.112 | ▲1.871 | ▲0.991 |
| Quick Ratio | 3.313 | ▲1.156 | ▲0.217 |
| Solvency Ratio | -0.081 | ▼-0.060 | ▲0.069 |
| Cash Ratio | 1.509 | ▲0.609 | ▲0.425 |
| Price To Earnings Ratio | -96.265 | ▼-24.613 | ▼-54.227 |
| Price To Earnings Growth Ratio | -2.013 | ▼-3.318 | ▼-1.158 |
| Forward Price To Earnings Growth Ratio | -2.013 | ▼-3.318 | ▼-1.158 |
| Price To Earnings Diluted Ratio | -96.265 | ▼-24.613 | ▼-54.227 |
| Price To Earnings Diluted Growth Ratio | -2.013 | ▼-3.318 | ▼-1.158 |
| Price To Book Ratio | 11.698 | ▲4.678 | ▲5.824 |
| Price To Sales Ratio | 6.693 | ▲2.799 | ▲2.994 |
| Price To Free Cash Flow Ratio | -513.885 | ▼-66820.416 | ▼-13665.477 |
| Price To Operating Cash Flow Ratio | 1856.189 | ▲1695.357 | ▲1474.022 |
| Debt To Assets Ratio | 0.305 | ▼-0.032 | ▼-0.028 |
| Debt To Equity Ratio | 0.525 | ▼-0.136 | ▼-0.111 |
| Debt To Capital Ratio | 0.344 | ▼-0.054 | ▼-0.043 |
| Long Term Debt To Capital Ratio | 0.273 | ▼-0.041 | ▼-0.029 |
| Financial Leverage Ratio | 1.720 | ▼-0.240 | ▼-0.184 |
| Working Capital Turnover Ratio | 2.722 | ▼-0.247 | ▲0.562 |
| Operating Cash Flow Ratio | 0.035 | ▼-0.114 | ▲0.281 |
| Operating Cash Flow Sales Ratio | 0.004 | ▼-0.021 | ▲0.050 |
| Free Cash Flow Operating Cash Flow Ratio | -3.612 | ▼-3.615 | ▼-4.700 |
| Debt Service Coverage Ratio | 0.025 | ▼-0.716 | ▲11.416 |
| Interest Coverage Ratio | -1.019 | ▼-0.619 | ▲14.049 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 0.012 | ▼-0.054 | ▲0.100 |
| Capital Expenditure Coverage Ratio | 0.217 | ▼-0.786 | ▲0.295 |
| Dividend Paid And Capex Coverage Ratio | 0.217 | ▼-0.786 | ▲0.295 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 8017.220 | ▲7890.471 | ▲6401.448 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.51B | $729.4M | $292.9M | $420.0M | $386.2M | |
| Enterprise value | $1.54B | $770.5M | $331.1M | $472.1M | $420.9M | |
| EV / Sales | 6.83x | 4.11x | 2.08x | 3.41x | 3.31x | |
| EV / Op. cash flow | 1895.70x | 169.90x | -57.93x | -29.39x | -31.40x | |
| EV / Free cash flow | -524.82x | 70045.80x | -16.05x | -12.65x | -10.07x | |
| EV / EBITDA | 8017.22x | 126.75x | -24.84x | -20.12x | -20.15x | |
| Net debt / EBITDA | 167.09x | 6.77x | -2.87x | -2.22x | -1.66x | |
| Current ratio | 5.11x | 3.24x | 2.89x | 4.13x | 5.23x | |
| Income quality | -0.05x | -0.46x | 0.26x | 0.56x | 0.50x | |
| Graham net-net | -$0 | -$1 | -$1 | -$0 | $0 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 196.3% | 566.8% | 115.0% | 102.2% | 105.3% | |
| Working capital | $96.9M | $68.6M | $57.6M | $74.3M | $102.8M | |
| Invested capital | $198.1M | $173.1M | $166.4M | $171.6M | $183.7M | |
| Return on assets | -7.1% | -4.9% | -11.0% | -14.8% | -13.0% | |
| Operating ROA | -3.7% | -1.6% | -10.9% | -14.7% | -12.4% | |
| Return on tangible assets | -7.3% | -5.0% | -11.3% | -15.1% | -13.2% | |
| Return on equity | -12.2% | -9.6% | -22.7% | -28.7% | -24.0% | |
| Return on invested capital | -3.9% | -1.9% | -12.8% | -17.2% | -13.7% | |
| Return on capital employed | -4.0% | -1.9% | -12.9% | -17.3% | -13.8% | |
| Earnings yield | -1.0% | -1.4% | -7.4% | -6.9% | -7.0% | |
| Free cash flow yield | -0.2% | 0.0% | -7.0% | -8.9% | -10.8% | |
| Capex / Op. cash flow | 461.2% | 99.8% | -261.0% | -132.3% | -211.9% | |
| Capex / Depreciation | 45.7% | 57.7% | 268.6% | 437.9% | 599.0% | |
| Capex / Sales | 1.7% | 2.4% | 9.4% | 15.3% | 22.3% | |
| SG&A / Sales | 63.2% | 62.7% | 72.9% | 81.5% | 83.0% | |
| R&D / Sales | 14.6% | 14.8% | 17.2% | 18.5% | 19.0% | |
| Stock comp / Sales | 13.4% | 8.5% | 9.1% | 11.3% | 8.6% | |
| Intangibles / Total assets | 3.0% | 2.7% | 2.3% | 1.9% | 1.4% | |
| Days sales outstanding | 42d | 47d | 58d | 58d | 52d | |
| Days payables outstanding | 18d | 64d | 116d | 110d | 94d | |
| Operating cycle | 310d | 314d | 284d | 290d | 318d | |
| Cash conversion cycle | 292d | 250d | 168d | 180d | 223d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+106.6%EV / Sales ▲+66.2%EV / EBITDA ▲+6225.3%EV / Op. cash flow ▲+1725.796Earnings yield ▲+0.003
Profitability
Return on equity ▼-0.026Return on assets ▼-0.022Return on invested capital ▼-0.020Return on capital employed ▼-0.021Operating ROA ▼-0.020Income quality ▲+0.403Tax burden 0.000
Efficiency
Days sales outstanding ▼-4.552Days payables outstanding ▼-46.217Operating cycle ▼-4.235Cash conversion cycle ▲+41.982Capex / Sales ▼-0.008R&D / Sales ▼-0.002
Balance-sheet strength
Current ratio ▲+1.871Net debt / EBITDA ▲+160.322Working capital ▲+28259000.000Invested capital ▲+25013000.000Intangibles / Total assets ▲+0.003
Change over 5 years
Valuation
Market cap ▲+290.3%EV / Sales ▲+106.8%EV / EBITDA ▲+39888.8%EV / Op. cash flow ▲+1927.095Earnings yield ▲+0.059
Profitability
Return on equity ▲+0.118Return on assets ▲+0.059Return on invested capital ▲+0.098Return on capital employed ▲+0.099Operating ROA ▲+0.087Income quality ▼-0.548Tax burden 0.000
Efficiency
Days sales outstanding ▼-9.627Days payables outstanding ▼-76.058Operating cycle ▼-8.009Cash conversion cycle ▲+68.049Capex / Sales ▼-0.206R&D / Sales ▼-0.044
Balance-sheet strength
Current ratio ▼-0.118Net debt / EBITDA ▲+168.750Working capital ▼-5890000.000Invested capital ▲+14400000.000Intangibles / Total assets ▲+0.017
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2019-06-24 | Donna Shalala | Sale (Full) | $1,001 - $15,000 |
| 2019-04-16 | Donna Shalala | Purchase | $1,001 - $15,000 |
Recent news
- 2026-09-01 Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference ALACHUA, Fla. and TAMPA, Fla.
- 2026-08-26 Axogen Inc (AXGN) Stock Up 3.3% but GF Value Says Overvalued -- GF Score: 64/100 On August 26, 2026, Axogen Inc (AXGN) shares rose 3.3% to a current price of $51.58, continuing a strong upward trend. Over the past year, the stock has surged
- 2026-08-26 Here Are Wednesday’s Top Wall Street Analyst Research Calls: Atlassian, Dick’s Sporting Goods, EPAM Systems, GoDaddy, Intuit, Jersey Mike’s Subs, JFrog, Lattice Semiconductor, and More Wall Street analysts are reshuffling their bets ahead of a critical inflation report and NVIDIA earnings that could jolt markets in either direction. Find out which names got upgraded, cut, or newly covered before the opening bell Wednesday.
- 2026-08-03 Axogen: The Regulatory Moat Is Becoming A Commercial Flywheel Axogen is transforming from a niche tissue supplier into a comprehensive nerve care platform, underpinned by FDA approval, stronger reimbursement, and expanding clinical evidence. Q2 2026 revenue grew 23.1% to $69.7M, with raised full-year guidance and strong elective market traction, though gross margin declined due to product mix and biologic costs. Avance''s FDA biologic approval grants 12 years of exclusivity, regulatory credibility, and improved payer coverage, positioning AXGN as a category leader with significant market opportunity.
- 2026-07-30 AxoGen (NASDAQ:AXGN) Shares Gap Down Following Weak Earnings AxoGen, Inc. (NASDAQ: AXGN - Get Free Report)''s stock price gapped down prior to trading on Wednesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $41.15, but opened at $38.31. AxoGen shares last traded at $44.5120, with a volume of 317,776 shares trading hands. The medical equipment provider reported
- 2026-07-29 Axogen, Inc. (AXGN) Q2 2026 Earnings Call Transcript Axogen, Inc. (AXGN) Q2 2026 Earnings Call Transcript
- 2026-07-29 AxoGen Q2 Earnings Call Highlights AxoGen NASDAQ: AXGN reported second-quarter 2026 revenue of $69.7 million, up 23.1% from a year earlier, as demand for its Avance nerve graft and broader product portfolio increased across its target markets. The company raised its full-year revenue outlook to at least $279 million, representing growth of at least 24%, while lowering its gross-margin expectation to at least 73% due to product-mix changes tied to faster-than-expected growth in breast reconstruction.
- 2026-07-29 AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates AxoGen (AXGN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.12 per share a year ago.
- 2026-07-29 Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology /PRNewswire/ -- Trace Biosciences, Inc., a clinical-stage biotechnology company developing nerve-targeted imaging agents, today announced it has received a
- 2026-07-29 Axogen, Inc. Reports Second Quarter 2026 Financial Results ALACHUA, Fla. and TAMPA, Fla.